Pharmacological treatment of pathologic aggression in children

References

• Aman MG, De Smedt G, Derivan A, et al. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. American Journal of Psychiatry 2002; 159: 1337–1346
   PubMed Web of Science ®Google Scholar
• Aman MG, Binder C, Turgay A. Risperidone effects in the presentation/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. Journal of Child and Adolescent Psychopharmacology 2004; 14(2)243–254
   PubMed Web of Science ®Google Scholar
• Armenteros JL, Lewis JE, Davalos M. Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: A placebo-controlled pilot study. Journal of the American Academy of Child and Adolescent Psychiatry 2007; 46(5)558–565
   PubMed Web of Science ®Google Scholar
• Buitelaar JK, van der Gaag RJ, Cohen-Kettenis P, et al. A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. Journal of Clinical Psychiatry 2001; 62: 239–248
   PubMed Web of Science ®Google Scholar
• Campbell M, Small AM, Green WH, et al. Behavioral efficacy of haloperidol and lithium carbonate. Archives of General Psychiatry 1984; 41: 650–656
   PubMed Web of Science ®Google Scholar
• Campbell M, Gonzalez NM, Silva RR. The pharmacological treatment of conduct disorders and rage outbursts. Psychiatric Clinics of North America 1992; 15: 69–85
   PubMed Web of Science ®Google Scholar
• Campbell M, Adams PB, Small AM, et al. Lithium in hospitalized aggressive children with conduct disorder: Double blind and placebo controlled study. Journal of the American Academy of Child and Adolescent Psychiatry 1995; 34: 445–453
   PubMed Web of Science ®Google Scholar
• Campbell M, Armenteros JL, Malone RP, et al. Neuroleptic-related dyskinesia in autistic children: A prospective, longitudinal study. Journal of the American Academy of Child and Adolescent Psychiatry 1997; 36: 835–843
   PubMed Web of Science ®Google Scholar
• Donovan SJ, Stewart JW, Nunes EV, et al. Divalproex treatment for youth with explosive temper and mood lability: A double-blind, placebo-controlled crossover design. American Journal of Psychiatry 2000; 157: 818–820
   PubMed Web of Science ®Google Scholar
• Fergusson DM, Horwood LJ, Ridder EM. Conduct and attentional problems in childhood and adolescence and later substance use, abuse, and dependence: Results of a 25-year longitudinal study. Drug and Alcohol Dependence 2007; 88 (Suppl. 1)S14–26
   PubMed Web of Science ®Google Scholar
• Findling RL, McNamara NK, Branicky LA, et al. A double-blind pilot study of risperidone in the treatment of conduct disorder. Journal of the American Academy of Child and Adolescent Psychiatry 2000; 39: 509–516
   PubMed Web of Science ®Google Scholar
• Findling RL. Treatment of aggression in children. Journal of Clinical Psychiatry 2003; 5(Suppl. 6)5–9
   Google Scholar
• Findling RL, Kusumakar V, Daneman D, et al. Prolactin levels during long-term risperidone treatment in children and adolescents. Journal of Clinical Psychiatry 2003; 64: 1362–1369
   PubMed Web of Science ®Google Scholar
• Findling RL, Aman MG, Eerdekens M, et al. Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. American Journal of Psychiatry 2004; 161: 677–684
   PubMed Web of Science ®Google Scholar
• Findling RL, McNamara NK. A typical antipsychotics in the treatment of children and adolescents: Clinical applications. Journal of Clinical Psychiatry 2004; 65(Suppl. 6)30–44
   PubMed Web of Science ®Google Scholar
• Findling R, Blumer J, Kauffman R, et al. Pharmacokinetic effects of aripiprazole in children and adolescents with conduct disorder. International Journal of Neuropsychopharmacology 2004; 7: S440
   Google Scholar
• Findling RL, Reed MD, O’Riordan MA, et al. Effectiveness, safety, and pharmacokinetics of quetiapine in aggressive children with conduct disorder. Journal of the American Academy of Child and Adolescent Psychiatry 2006; 45: 792–800
   PubMed Web of Science ®Google Scholar
• Findling RL, Reed MD, O’Riordan MA, et al. A 26-week open-label study of quetiapine in children with conduct disorder. Journal of Child and Adolescent Psychopharmacology 2007; 17(1)1–9
   PubMedGoogle Scholar
• Gillberg C. Typical neuroleptics in child and adolescent psychiatry. European Child and Adolescent Psychiatry 2000; 9(Suppl. 1)I/2–I/8
   Google Scholar
• Greenhill LL, Solomon M, Pleak R, et al. Molindone hydrochloride treatment of hospitalized children with conduct disorder. Journal of Clinical Psychiatry 1985; 46: 20–25
   PubMed Web of Science ®Google Scholar
• Jensen PS, Youngstrom EA, Steiner H, Findling RL, et al. Consensus report on impulsive aggression as a symptom across diagnostic categories in child psychiatry: Implications for medication studies. Journal of the American Academy of Child and Adolescent Psychiatry 2007; 46(3)309–322
   PubMed Web of Science ®Google Scholar
• Keenan K, Wakschlag LS, Danis B, et al. Further evidence of the reliability and validity of DSM-IV ODD and CD in preschool children. Journal of the American Academy of Child and Adolescent Psychiatry 2007; 46(4)467–468
   Google Scholar
• Kim-Cohen J, Arseneault L, Caspi A, et al. Validity of DSM-IV conduct disorder in 41/2–5-year-old children: A longitudinal epidemiological study. American Journal of Psychiatry 2005; 162: 1108–1117
   PubMed Web of Science ®Google Scholar
• Klein RG, Abikoff H, Klass E, et al. Clinical efficacy of methylphenidate in conduct disorder with and without attention deficit hyperactivity disorder. Archives of General Psychiatry 1997; 54: 1073–1080
   PubMed Web of Science ®Google Scholar
• Malone RP, Delaney MA, Luebbert JF, et al. A double-blind placebo-controlled study of lithium in hospitalized aggressive children and adolescents with conduct disorder. Archives of General Psychiatry 2000; 57: 649–654
   PubMed Web of Science ®Google Scholar
• Mesman J, Koot HM. Early preschool predictors of preadolescent internalizing and externalizing DSM-IV diagnoses. Journal of the American Academy of Child and Adolescent Psychiatry 2001; 40(9)1029–1036
   PubMed Web of Science ®Google Scholar
• MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Archives of General Psychiatry 1999; 56: 1073–1086
   PubMed Web of Science ®Google Scholar
• Pandina GJ, Aman MG, Findling RL. Risperidone in the management of disruptive behavior disorders. Journal of Child and Adolescent Psychopharmacology 2006; 16: 379–392
   PubMed Web of Science ®Google Scholar
• Pappadopulos E, MacIntyre II JC, Crimson ML, et al. Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II. Journal of the American Academy of Child and Adolescent Psychiatry 2003; 42(2)145–161
   PubMed Web of Science ®Google Scholar
• Patel NC, Sanchez RJ, Johnsrud MT, Crimson ML. Trends in antipsychotic use in a Texas Medicaid population of children and adolescents: 1996–2000. Journal of Child and Adolescent Psychopharmacology 2002; 12: 1219–1242
   Google Scholar
• Patel NC, Crimson ML, Hoagwood K, et al. Trends in the use of typical and atypical antipsychotics in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry 2005; 44: 548–556
   PubMed Web of Science ®Google Scholar
• Research Units on Pediatric Phychopharmacology Autism Network. Risperidone in children with autism and serious behavioral problems. New England Journal of Medicine 2002; 347: 314–321
   PubMedGoogle Scholar
• Reyes M, Buitelaar J, Toren P, et al. A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. American Journal of Psychiatry 2006a; 163: 402–410
   PubMed Web of Science ®Google Scholar
• Reyes M, Olah R, Csaba K, et al. Long-term safety and efficacy of risperidone in children with disruptive behaviour disorders. Results of a 2-year extension study. European Child Adolescent Psychiatry 2006b; 15: 97–104
   PubMed Web of Science ®Google Scholar
• Rifkin A, Karajgi B, Dicker R, et al. Lithium treatment of conduct disorders in adolescents. American Journal of Psychiatry 1997; 154: 554–555
   PubMedGoogle Scholar
• Satterfield JH, Faller KJ, Crinella FM, et al. A 30-year prospective follow-up study of hyperactive boys with conduct problems: Adult criminality. Journal of American Academy of Child and Adolescent Psychiatry 2007; 46: 601–610
   PubMed Web of Science ®Google Scholar
• Schur SB, Sikich L, Findling RL, et al. Treatment ecommendations for the use of antipsychotics for aggressive youth (TRAAY). I: A review. Journal of the American Academy of Child and Adolescent Psychiatry 2003; 42(2)132–144
   PubMed Web of Science ®Google Scholar
• Scott S. Aggressive behaviour in childhood. British Medical Journal 1998; 316: 202–206
   PubMed Web of Science ®Google Scholar
• Sikich L, Hamer RM, Bashford RA, et al. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: A double-blind, randomized, 8-week trial. Neuropsychopharmacaology 2004; 29: 133–145
   PubMed Web of Science ®Google Scholar
• Snyder R, Turgay A, Aman MG, et al. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. Journal of the American Academy of Child and Adolescent Psychiatry 2002; 41: 1026–1036
   PubMed Web of Science ®Google Scholar
• Staller JA. Psychopharmacologic treatment of aggressive preschoolers: a chart review. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 131–135
   PubMed Web of Science ®Google Scholar
• Van Bellinghen M, De Troch C. Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: A double blind, placebo-controlled pilot trial. Journal of Child and Adolescent Psychopharmacology 2001; 11: 4–13
   Google Scholar
• Zigler E, Taussig C, Black K. Early childhood intervention. A promising preventative for juvenile delinquency. American Psychologist 1992; 47(8)997–1006
   PubMed Web of Science ®Google Scholar